Progress with covalent small-molecule kinase inhibitors
- PMID: 29337202
- DOI: 10.1016/j.drudis.2018.01.035
Progress with covalent small-molecule kinase inhibitors
Abstract
With reduced risk of toxicity and high selectivity, covalent small-molecule kinase inhibitors (CSKIs) have emerged rapidly. Through the lens of structural system pharmacology, here we review this rapid progress by considering design strategies and the challenges and opportunities offered by current CSKIs.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
